Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $34.75 USD
Change Today -0.0099 / -0.03%
Volume 78.9K
LJPC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 1:51 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

George F. Tidmarsh M.D., Ph.D.

Chief Executive Officer, President, Secretary and Director,La Jolla Pharmaceutical Co.
AgeTotal Calculated CompensationThis person is connected to 10 board members in 1 different organizations across 8 different industries.

See Board Relationships
55$2,705,909
As of Fiscal Year 2014

Background*

Dr. George F. Tidmarsh, M.D., Ph.D., has been the Chief Executive Officer, President and Secretary of La Jolla Pharmaceutical Co. since January 19, 2012. Dr. Tidmarsh served as an Executive of Horizon Pharma, Inc. He founded Nuveta Inc. and served as its President and Chief Executive Officer. He founded Metronome Therapeutics Inc., in 2007. He served as the Chief Executive Officer of Solana Therapeutics, Inc. He Co-founded Horizon Pharma USA Inc. in 2005 and served as ...

Read Full Background

Corporate Headquarters*

4660 La Jolla Village Drive
San Diego, California 92122

United States

Phone: 858-207-4264
Fax: --

Board Members Memberships*

2012-Present
Chief Executive Officer, President, Secretary and Director

Education*

BS
Stanford University
PhD
Stanford University School of Medicine
MD
Stanford University School of Medicine

Other Affiliations*

Annual Compensation*

Salary$470,000
Total Annual Compensation$470,000

Stock Options*

All Other Compensation$63,930
Unexercisable Options181,000
Unexercisable Options Value$1,377,410
Total Value of Options$1,377,410
Total Number of Options181,000

Total Compensation*

Total Annual Cash Compensation$768,930
Total Short Term Compensation$470,000
Other Long Term Compensation$63,930
Total Calculated Compensation$2,705,909
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LJPC:US $34.75 USD -0.0099

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ian C. Read Chairman, Chief Executive Officer and Chairman of Executive Committee
Pfizer Inc.
$1.8M
Andrew Philip Witty Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee
GlaxoSmithKline plc
2.0M GBP
Kenneth C. Frazier Chairman, Chief Executive Officer and President
Merck & Co. Inc.
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.1M GBP
Joseph Jimenez Jr., MBAChief Executive Officer
Novartis AG
SFr.6.1M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LA JOLLA PHARMACEUTICAL CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.